Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers

Head and Neck

Volumn 37, Issue 3, 2015, Pages 449-459

  Wallis, Sebastian P ^a   Stafford, Nicholas D ^a   Greenman, John ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cancer; Head; Microenvironment; Neck; Prognosis

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; IMMUNOMODULATING AGENT; INTERLEUKIN 10; IRX 2; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; DENDRITIC CELL; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; IN VITRO STUDY; IN VIVO STUDY; LARYNX; LARYNX SQUAMOUS CELL CARCINOMA; MEDLINE; MOUTH CANCER; MOUTH CAVITY; MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX; NASOPHARYNX CARCINOMA; OROPHARYNX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TISSUE MICROARRAY; TUMOR CELL; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; CANCER STAGING; FEMALE; HEAD AND NECK TUMOR; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TUMOR INVASION;

BIOMARKERS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MICROENVIRONMENT;

EID: 84923090884     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23736     Document Type: Review

References (96)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Murdoch D. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol 2007;19:216-221.
3. Hashibe M, Hunt J, Wei M, Buys S, Gren L, Lee YC. Tobacco, alcohol, body mass index, physical activity, and the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort. Head Neck 2013;35:914-922.
4. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-2054.
5. Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002;8:3187-3192.
6. Tralongo V, Rodolico V, Luciani A, Marra G, Daniele E. Prognostic factors in oral squamous cell carcinoma. A review of the literature. Anticancer Res 1999;19:3503-3510.
7. Shaw RJ, Lowe D, Woolgar JA, et al. Extracapsular spread in oral squamous cell carcinoma. Head Neck 2010;32:714-722.
8. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3-15.
9. Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006;130:103-124.
10. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-5912.
11. Senovilla L, Vacchelli E, Galon J, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012;1:1323-1343.
12. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
13. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727.
14. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007;204:345-356.
15. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012;2012:425476.
16. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002;2:957-964.
17. Morandi B, Mortara L, Chiossone L, et al. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS One 2012;7:e39170.
18. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009;27:451-483.
19. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977-4982.
20. Martinelli-Kläy CP, Mendis BR, Lombardi T. Eosinophils and oral squamous cell carcinoma: a short review. J Oncol 2009;2009:310132.
21. Fridman WH, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 2011;344:1-24.
22. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58:449-459.
23. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-2593.
24. Ladoire S, Mignot G, Dabakuyo S, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011;224:389-400.
25. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-2872.
26. Pilla D, Bosisio FM, Marotta R, et al. Tissue microarray design and construction for scientific, industrial and diagnostic use. J Pathol Inform 2012;3:42.
27. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986;95:142-152.
28. Snyderman CH, Heo DS, Chen K, Whiteside TL, Johnson JT. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck 1989;11:331-336.
29. Harasymczuk M, Gooding W, Kruk-Zagajewska A, et al. Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy. Eur Arch Otorhinolaryngol 2013;270:1105-1114.
30. Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005;23:8932-8941.
31. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-472.
32. Bron L, Jandus C, Andrejevic-Blant S, et al. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 2013;132:E85-E93.
33. Sun DS, Zhao MQ, Xia M, Li L, Jiang YH. The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers. Med Oncol 2012;29:707-713.
34. Loose D, Signore A, Bonanno E, et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. Cancer Biother Radiopharm 2008;23:25-33.
35. Alrawi SJ, Tan D, Stoler DL, et al. Tissue eosinophilic infiltration: a useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia. Cancer J 2005;11:217-225.
36. Katayama A, Takahara M, Kishibe K, et al. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int J Oncol 2011;38:1219-1226.
37. Vanselow B, Eble MJ, Rudat V, Wollensack P, Conradt C, Dietz A. Oxygenation of advanced head and neck cancer: prognostic marker for the response to primary radiochemotherapy. Otolaryngol Head Neck Surg 2000;122:856-862.
38. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-3403.
39. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005;5:42.
40. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
41. Clatot F, Picquenot JM, Choussy O, et al. Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 2011;47:1062-1068.
42. Thurlow JK, Peña Murillo CL, Hunter KD, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010;28:2881-2888.
43. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005;29:167-178.
44. Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, Hashimoto K. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:744-752.
45. Costa NL, Alencar Rde C, Valadares MC, Silva TA, Mendonc¸a EF, Batista AC. The clinicopathological significance of the expression of granzyme B in oral squamous cell carcinoma. Oral Oncol 2010;46:185-189.
46. Tabachnyk M, Distel LV, Büttner M, et al. Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer. Oral Oncol 2012;48:594-601.
47. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011;47:1148-1153.
48. Zancope E, Costa NL, Junqueira-Kipnis AP, et al. Differential infiltration of CD8+ and NK cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med 2010;39:162-167.
49. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91:2136-2147.
50. Moreira G, Fulgêencio LB, DE Mendonc¸a EF, Leles CR, Batista AC, DA Silva TA. T regulatory cell markers in oral squamous cell carcinoma: relationship with survival and tumor aggressiveness. Oncol Lett 2010;1:127-132.
51. Liang YJ, Liu HC, Su YX, et al. Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients. Oral Oncol 2011;47:566-570.
52. Nibali L, Fedele S, D'Aiuto F, Donos N. Interleukin-6 in oral diseases: a review. Oral Dis 2012;18:236-243.
53. Chen CJ, Sung WW, Lin YM, et al. Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma. PLoS One 2012;7:e50104.
54. Chen MF, Wang WH, Lin PY, Lee KD, Chen WC. Significance of the TGF-β1/IL-6 axis in oral cancer. Clin Sci (Lond) 2012;122:459-472.
55. Elahi M, Rakhshan V, Ghasemian NT, Moshref M. Prognostic value of transforming growth factor beta 1 [TGF-β1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers 2012;17:21-27.
56. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-181.
57. Chuang CY, Sung WW, Wang L, et al. Differential impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas. PLoS One 2012;7:e47541.
58. Kindt N, Lechien J, Decaestecker C, et al. Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res 2012;32:4499-4505.
59. Tsuzuki H, Sunaga H, Ito T, Narita N, Sugimoto C, Fujieda S. Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas. Arch Otolaryngol Head Neck Surg 2005;131:1071-1078.
60. Lin YT, Chuang HC, Chen CH, et al. Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma. BMC Cancer 2012;12:194.
61. Perotti C, Liu R, Parusel CT, et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res 2008;10:R94.
62. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 2008;14: 1317-1324.
63. Bauernhofer T, Pichler M, Wieckowski E, et al. Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck. Br J Cancer 2011;104:1641-1648.
64. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011;29:4294-4301.
65. Rainsbury JW, Ahmed W, Williams HK, Roberts S, Paleri V, Mehanna H. Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 2013;35:1048-1055.
66. Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120:1756-1772.
67. Wansom D, Light E, Thomas D, et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 2012;122:121-127.
68. Nasman A, Romanitan M, Nordfors C, et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012;7:e38711.
69. Distel LV, Fickenscher R, Dietel K, et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol 2009;45:e167-e174.
70. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007;86:506-511.
71. Ritta M, Landolfo V, Mazibrada J, et al. Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer. New Microbiol 2013;36:133-144.
72. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009;9:292.
73. Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999;136:1-9.
74. Malecki K, Gliński B, Mucha-Malecka A, Roszkowski K, Hetnal M. Predictive and prognostic value of p53, Ki-67 and EGFR in patients with advanced oral cavity and oropharyngeal cancer treated with induction chemotherapy [in Polish]. Przegl Lek 2012;69:5-8.
75. Chandarana SP, Lee JS, Chanowski EJ, et al. Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck 2013;35:1083-1090.
76. Lin JY, Li XY, Tadashi N, Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer 2011;30:280-286.
77. Morra B, Ferrero V, Bussi M, Pacchioni D, Cerrato M, Bussolati G. Peri and intratumoral macrophage infiltration in laryngeal carcinoma. an immunohistochemical study. Acta Otolaryngol 1991;111:444-448.
78. Gabriel A, Namyslowski G, Ziólkowski A, Morawski K, Steplewska-Mazur K, Urbaniec P. Immunohistochemical analysis of lymphocytic infiltration in the tumor microenvironment in patients operated on for laryngeal cancer. Eur Arch Otorhinolaryngol 1999;256:384-387.
79. Gallo O, Libonati GA, Gallina E, et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1991;117:1007-1010.
80. Yip WK, Abdullah MA, Yusoff SM, Seow HF. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol 2009;155:412-422.
81. Zea AH, Curti BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-1335.
82. Liao B, Zhong BL, Li Z, Tian XY, Li Y, Li B. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. J Surg Oncol 2010;102:844-851.
83. Li J, Mo HY, Xiong G, et al. Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem 2012;287:35484-35495.
84. Hsu MC, Hsiao JR, Chang KC, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010;23:1393-1403.
85. Ma CX, Jia TC, Li XR, Zhand ZF, Yiao CB. Langerhans cells in nasopharyngeal carcinoma in relation to prognosis. In Vivo 1995;9:225-229.
86. Gallo O, Bianchi S, Giannini A, Gallina E, Libonati GA, Fini-Storchi O. Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope 1991;101:487-493.
87. Cai MB, Han HQ, Bei JX, et al. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma. Int J Biol Sci 2012;8:891-900.
88. Czystowska M, Han J, Szczepanski MJ, et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ 2009;16:708-718.
89. Berinstein NL, Wolf GT, Naylor PH, et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 2012;61:771-782.
90. Timar J, Ladanyi A, Forster-Horvath C, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 2005;23:3421-3432.
91. Feinmesser M, Okon E, Schwartz A, et al. Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line. Eur Arch Otorhinolaryngol 2004;261:359-368.
92. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008;113:1387-1395.
93. Cunha LL, Morari EC, Guihen AC, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012;77:918-925.
94. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29: 1949-1955.
95. Kim KY, Li S, Cha JD, Zhang X, Cha IH. Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck 2012;34:929-936.
96. Lin JY, Li XY, Tadashi N, Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer 2011;30:280-286.